Can I Take Green Tea Extract / EGCG with Evenity (Romosozumab)?

What Is Romosozumab (Evenity) and How Does It Work?

Romosozumab is a sclerostin-inhibiting monoclonal antibody approved by the FDA in April 2019 for the treatment of osteoporosis in postmenopausal women at high risk of fracture. It is given as two 105 mg subcutaneous injections (total 210 mg) once monthly for exactly 12 months. The drug works by binding and blocking sclerostin, a protein that ordinarily suppresses bone formation. By neutralizing sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual effect not seen with other anti-osteoporotic agents.

The FRAME and ARCH Trials

The FDA approval rested on two large randomized controlled trials. FRAME (N=7,180) compared romosozumab to placebo over 12 months and showed a 73% relative reduction in new vertebral fractures (P<0.001) [1]. The subsequent ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone, finding a 48% reduction in hip fracture at 24 months in the romosozumab-first arm (P<0.001) [2].

Both trials identified a cardiovascular safety signal. The FDA label carries a black-box warning for myocardial infarction, stroke, and cardiovascular death. Patients with a myocardial infarction or stroke in the prior year should not receive romosozumab [3].

How Romosozumab Is Eliminated

Romosozumab, like other therapeutic monoclonal antibodies, is eliminated through proteolytic catabolism into amino acid fragments. It does not undergo meaningful hepatic CYP450 metabolism. This distinction matters: supplements that inhibit or induce CYP enzymes (CYP1A2, CYP3A4, CYP2D6) have minimal direct effect on romosozumab plasma levels. The interaction concern with EGCG is therefore not primarily pharmacokinetic in nature.

What Is EGCG and Why Is It Used?

Epigallocatechin gallate (EGCG) is the predominant polyphenol catechin in green tea. In brewed tea, a standard 8 oz cup delivers roughly 50-150 mg of EGCG, depending on brewing time and leaf variety. Concentrated green tea extract supplements typically deliver 400-1,000 mg of EGCG per capsule, several times what a heavy tea drinker would consume from beverages.

Marketers of EGCG supplements cite potential benefits across antioxidant activity, metabolic health, and bone density. On the bone side, in vitro and animal data suggest EGCG may stimulate osteoblasts and suppress osteoclasts [4]. A 2017 randomized pilot study in postmenopausal women (N=171) found that 500 mg/day of green tea polyphenols combined with Tai Chi exercise modestly improved bone turnover markers over 24 weeks compared to placebo [5]. However, no large phase III trial has confirmed fracture reduction from EGCG alone in humans.

Forms and Doses Encountered in Clinical Practice

Patients taking romosozumab for osteoporosis often ask about EGCG because both are associated with bone health. The doses seen in clinical practice vary widely:

• Brewed green tea: 2-5 cups/day, approximately 100-400 mg EGCG total
• Standard green tea extract capsules: 400-500 mg EGCG/day
• High-potency extracts marketed for weight loss or antioxidants: 700-1,200 mg EGCG/day

The hepatotoxicity risk profile changes substantially across these tiers, and the tier matters when evaluating safety during romosozumab therapy.

The Hepatotoxicity Risk of High-Dose EGCG Supplements

This is the clinically significant concern when combining green tea extract with any drug that requires liver safety monitoring. High-dose EGCG is a recognized cause of drug-induced liver injury (DILI).

Case Reports and Mechanistic Data

The European Food Safety Authority (EFSA) published a comprehensive safety assessment in 2018 concluding that green tea extract doses at or above 800 mg/day are associated with a statistically significant increase in liver enzyme elevations [6]. A 2020 systematic review of EGCG-associated DILI identified 78 case reports worldwide, with the majority occurring at concentrated supplement doses rather than from beverage consumption [7].

The proposed mechanism involves pro-oxidant quinone metabolites of EGCG that form at high intracellular concentrations, depleting glutathione and generating reactive oxygen species in hepatocytes [8]. This is paradoxically the opposite of the antioxidant effect EGCG displays at low beverage doses.

A 2023 National Toxicology Program report noted that when fasted animals were exposed to concentrated EGCG, hepatocellular necrosis occurred at lower doses than in fed animals, suggesting the fed-state matters clinically [9]. In humans, taking high-dose green tea extract supplements on an empty stomach appears to increase peak plasma EGCG concentrations and, with them, hepatotoxic risk.

Relevance to Romosozumab Therapy

Romosozumab itself does not carry a hepatotoxicity warning. However, any unexplained liver enzyme elevation during therapy complicates clinical management. Bone-specific alkaline phosphatase (a marker that romosozumab raises as a sign of bone formation) can be confounded by total alkaline phosphatase elevations from hepatic sources. If EGCG-induced liver enzyme rises occur, clinicians may incorrectly attribute them to romosozumab or may need to pause the 12-month injection series to investigate, disrupting the tightly timed treatment window.

A practical three-tier risk framework for EGCG use during romosozumab therapy:

| EGCG Tier | Approximate Daily Dose | Hepatotoxicity Risk | Recommendation | |---|---|---|---| | Brewed tea (2-5 cups) | 100-400 mg | Negligible | Generally acceptable | | Standard extract | 400-600 mg | Low to moderate | Discuss with prescriber; baseline LFTs advised | | High-potency extract | 700 mg or above | Moderate to high | Avoid during active Evenity therapy |

CYP Enzyme Interactions: Does EGCG Affect Romosozumab Levels?

As noted, romosozumab is not a CYP450 substrate, so CYP inhibition by EGCG does not directly alter romosozumab pharmacokinetics. This is an important clarification for patients who have read general supplement-drug interaction warnings.

CYP1A2 Inhibition by EGCG

EGCG does inhibit CYP1A2 in vitro and has shown modest in vivo inhibitory effects at doses above 800 mg/day [10]. CYP1A2 metabolizes drugs including clozapine, theophylline, and certain fluoroquinolones. Patients on romosozumab who are also taking CYP1A2-metabolized medications should be aware that simultaneously adding high-dose EGCG could increase plasma levels of those co-medications.

P-glycoprotein and ABCG2 Transporter Effects

A 2014 study in the Journal of Nutritional Biochemistry found that EGCG at concentrations achievable with supplement doses inhibits the breast cancer resistance protein ABCG2 [11]. ABCG2 is not a primary elimination pathway for romosozumab, but this finding is relevant for patients who co-administer other drugs dependent on this efflux transporter.

Net Pharmacokinetic Assessment

For romosozumab specifically, the CYP and transporter effects of EGCG are of low direct clinical significance. The interaction is better classified as primarily pharmacodynamic (shared liver stress potential) rather than pharmacokinetic.

What Published Guidelines and Databases Say

No dedicated romosozumab-EGCG interaction study exists in the peer-reviewed literature as of mid-2025. Interaction classification therefore relies on the individual safety profiles of each agent and general pharmacological principles.

FDA Labeling for Romosozumab

The Evenity prescribing information does not list green tea extract or EGCG as a contraindication or interaction, and it does not include hepatotoxicity as a drug-specific adverse effect [3]. The label's focus remains on cardiovascular risk and hypocalcemia (patients must be adequately supplemented with calcium and vitamin D).

EFSA and NTP Assessments of EGCG

The EFSA 2018 opinion is the most authoritative regulatory statement on EGCG safety. It states: "Intakes of EGCG of 800 mg/day or more from food supplements are associated with a statistically significant increase in the occurrence of elevated serum transaminases" [6]. This threshold is clinically useful for risk-stratifying patients.

The 2023 NTP report supports dose-dependency of liver effects and adds the fasting-state variable noted above [9].

Bone Health Guidelines

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines for postmenopausal osteoporosis recommend romosozumab as a first-line anabolic option for patients at very high fracture risk [12]. The guidelines do not address EGCG specifically but recommend that patients avoid supplements or substances that could interfere with the monitoring required during parenteral therapy.

The Endocrine Society's clinical practice guideline notes that the 12-month romosozumab course should not be interrupted unnecessarily, because the anabolic window of the drug is time-limited [13]. Liver enzyme elevations requiring workup would constitute exactly such an interruption.

Bone Health Claims for EGCG: What the Evidence Actually Shows

Some patients ask whether EGCG might add to romosozumab's bone-building effect. The evidence does not support a clinically meaningful additive bone benefit.

In Vitro and Animal Data

EGCG stimulates osteoblast differentiation through Wnt signaling and reduces RANKL-induced osteoclastogenesis in cell culture [4]. Animal studies in ovariectomized rodents show modest bone density preservation with EGCG supplementation [14]. These findings are mechanistically plausible but have not translated to confirmed fracture reduction in humans.

Human Clinical Data

The 2017 pilot RCT by Shen et al. (N=171, 24 weeks, 500 mg/day green tea polyphenols) found statistically significant improvements in bone-specific alkaline phosphatase and a trend toward reduced urinary 8-hydroxy-2-deoxyguanosine (oxidative stress marker), but did not report fracture outcomes [5]. Sample size and duration were insufficient to conclude fracture benefit.

No head-to-head or combination data exist for EGCG plus romosozumab. Given that romosozumab already delivers a dual anabolic-antiresorptive effect with demonstrated 73% vertebral fracture reduction at 12 months [1], any marginal additive bone effect from EGCG would be of secondary importance against the liver safety tradeoff at high doses.

Practical Guidance: What to Do If You Are Already Taking Both

Patients who are currently taking romosozumab and discover they have also been taking green tea extract supplements do not need to panic. The steps below provide a structured approach.

Step 1: Identify Your EGCG Dose

Check the supplement label for the EGCG content per serving. Many products list total green tea extract (e.g., 500 mg) and a percentage standardization (e.g., "45% EGCG"), meaning the actual EGCG dose is 225 mg in that example. Calculate actual EGCG milligrams, not total extract weight.

Step 2: Assess Your Current Liver Function

Contact your prescribing clinician for a baseline or repeat metabolic panel including AST, ALT, and total alkaline phosphatase. If LFTs are within normal limits and your EGCG dose is below 400 mg/day, ongoing supplementation at that dose while monitoring may be acceptable. If LFTs show any elevation above the upper limit of normal, discontinue EGCG immediately and retest in 4 weeks.

Step 3: Transition to Brewed Tea If Desired

Patients who want the potential antioxidant and metabolic benefits of green tea polyphenols during Evenity therapy may safely consume 2-4 cups of brewed green tea daily. This delivers approximately 100-300 mg EGCG, well below the 800 mg hepatotoxicity threshold established by EFSA [6].

Step 4: Timing and Re-introduction After Therapy

The romosozumab course lasts exactly 12 months. After the final injection, if a patient wishes to resume high-dose EGCG supplementation, a 2-month washout period from romosozumab (approximately 5 half-lives of the drug, given a terminal half-life of roughly 6.4 days) followed by a repeat LFT panel before resumption is a reasonable precaution, though no published protocol specifies this interval.

Monitoring Recommendations During Concurrent Use

For patients who continue any green tea extract supplement during romosozumab therapy with prescriber approval, a basic monitoring schedule reduces risk.

• Baseline LFTs before starting the combination (AST, ALT, alkaline phosphatase, total bilirubin)
• LFTs at month 3 of the 12-month romosozumab course if using supplements above 400 mg EGCG/day
• LFTs at month 6 for ongoing surveillance
• Immediate LFT recheck if any symptoms of liver stress appear: fatigue, right upper quadrant discomfort, jaundice, dark urine, or light stools
• Discontinue EGCG supplement if AST or ALT rises above 3 times the upper limit of normal; retest in 4 weeks to confirm resolution before attributing to supplement versus drug

Calcium and vitamin D supplementation must continue throughout romosozumab therapy regardless of EGCG use, per FDA labeling requirements [3].

Special Populations

Postmenopausal Women with Pre-Existing Liver Conditions

Women with non-alcoholic fatty liver disease (NAFLD), elevated baseline transaminases, or a history of DILI are at heightened risk from high-dose EGCG. Given that postmenopausal women are the primary population receiving romosozumab for osteoporosis, and that NAFLD prevalence in this group may reach 25-35% [15], clinicians should specifically screen for pre-existing liver pathology before permitting any EGCG supplementation during Evenity therapy.

Patients on Multiple Supplements

Patients presenting with polypharmacy supplement use (common in the osteoporosis demographic) may combine EGCG with other hepatotoxic supplements such as kava, black cohosh, or high-dose vitamin A. Cumulative hepatotoxic load should be assessed, not just individual supplement doses.